Equities

Insmed Inc

Insmed Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)73.15
  • Today's Change-0.66 / -0.89%
  • Shares traded1.76m
  • 1 Year change+208.26%
  • Beta1.0998
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments7801,148717
Total Receivables, Net413024
Total Inventory837067
Prepaid expenses242529
Other current assets, total------
Total current assets9291,273837
Property, plant & equipment, net10410296
Goodwill, net136136136
Intangibles, net646974
Long term investments--050
Note receivable - long term------
Other long term assets977651
Total assets1,3301,6561,244
LIABILITIES
Accounts payable695336
Accrued expenses15413699
Notes payable/short-term debt000
Current portion long-term debt/capital leases2.611.220.61
Other current liabilities, total------
Total current liabilities226190135
Total long term debt1,1821,155581
Total debt1,1851,156581
Deferred income tax------
Minority interest------
Other liabilities, total254223117
Total liabilities1,6621,568833
SHAREHOLDERS EQUITY
Common stock1.481.361.19
Additional paid-in capital3,1132,7822,674
Retained earnings (accumulated deficit)(3446)(2697)(2265)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.75)0.760.97
Total equity(332)88410
Total liabilities & shareholders' equity1,3301,6561,244
Total common shares outstanding148136119
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.